Previous 10 | Next 10 |
home / stock / cytk / cytk articles
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Stru...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the company is sched...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 550 points on Thursday. The Dow traded down 1.44% to...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday. The Dow traded down 0.65% to 39...
Cytokinetics, Inc. (NASDAQ:CYTK) shares are trading lower by 17.6% to $48.83 during Thursday’s session after the company announced the pricin...
Shares of NVIDIA Corporation (NASDAQ:NVDA) rose sharply in today's pre-market trading after the company reported better-than-expected financia...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Thursday. Shares of V.F. Corporation (NYSE:VFC) f...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced plans to offer, subject t...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety and Outcomes from FOREST-HCM Related to Withdrawal of Standard of Care Medications to b...
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...